Focus: Cancer Center Featured Story 2

Filters close
Newswise: Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma
Released: 29-May-2020 4:05 PM EDT
Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma
Rutgers Cancer Institute of New Jersey

Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.

Newswise: Decisions to Stray From Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis Shows
Released: 29-May-2020 1:25 PM EDT
Decisions to Stray From Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis Shows
Roswell Park Comprehensive Cancer Center

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, a new Roswell Park study shows.

Newswise: thota_swapna.jpg
Released: 29-May-2020 11:05 AM EDT
Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers
Roswell Park Comprehensive Cancer Center

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.

Newswise: Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
28-May-2020 11:05 AM EDT
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
Dana-Farber Cancer Institute

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

Newswise: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Released: 29-May-2020 10:30 AM EDT
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
University of Texas M. D. Anderson Cancer Center

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
Released: 29-May-2020 10:20 AM EDT
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
University of Texas M. D. Anderson Cancer Center

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

Newswise: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
Released: 29-May-2020 10:05 AM EDT
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
University of Texas M. D. Anderson Cancer Center

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Newswise: Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Released: 29-May-2020 8:00 AM EDT
Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Yale Cancer Center

Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.

Released: 28-May-2020 6:05 PM EDT
Phase III Trial Shows Avelumab an Immunotherapy Treatment for Advanced Urothelial Cancer Prolongs Overall Survival
Seattle Cancer Care Alliance

During a plenary session of the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, findings will be presented from the global phase III JAVELIN Bladder 100 randomized study conducted by investigators from Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center and University of Washington Medicine along with several other research centers. The results demonstrated significantly prolonged overall survival of patients with locally advanced (unresectable) or metastatic urothelial cancer when treated with first-line immunotherapy avelumab plus best supportive care (BSC) compared to BSC alone (following disease control on induction chemotherapy).

Newswise: Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
28-May-2020 5:00 PM EDT
Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
Yale Cancer Center

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.


Showing results

110 of 10

close
0.68002